UB Paderborn / Katalog / Suche / in CDI

Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma

International journal of cancer, 2019-01, Vol.144 (1), p.190-199

2019

Link zum Volltext

Verfügbarkeit prüfen

Polyglactin 910 suture compared with polyglactin 910 coated with triclosan in dental implant surgery: randomized clinical trial

International journal of oral and maxillofacial surgery, 2019-10, Vol.48 (10), p.1367-1371

2019

Link zum Volltext

Verfügbarkeit prüfen

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing

Lung cancer (Amsterdam, Netherlands), 2020-10, Vol.148, p.105-112

2020

Link zum Volltext

Verfügbarkeit prüfen

Retrospective study of paclitaxel in advanced therapy lines in the treatment of SCLC

Annals of oncology, 2018-10, Vol.29, p.viii600-viii600

2018

Link zum Volltext

Verfügbarkeit prüfen

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial

Annals of oncology, 2018-10, Vol.29, p.viii544-viii544

2018

Link zum Volltext

Verfügbarkeit prüfen

TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii516-viii517

2018

Link zum Volltext

Verfügbarkeit prüfen

Durvalumab in frail and elder patients with stage four NSCLC: The DURATION trial

Annals of oncology, 2018-10, Vol.29, p.viii546-viii547

2018

Link zum Volltext

Verfügbarkeit prüfen

Ultra-early response capturing in the treatment of non-squamous NSCLC using diffusion-weighted MRI: A prospective multicenter study

Annals of oncology, 2018-10, Vol.29, p.viii546-viii546

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer

ESMO open, 2021-06, Vol.6 (3), p.100161-100161, Article 100161

2021

Link zum Volltext

Verfügbarkeit prüfen

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

The New England journal of medicine, 2018-12, Vol.379 (23), p.2220-2229

2018

Link zum Volltext

Verfügbarkeit prüfen

Real‐world data for precision cancer medicine—A European perspective

Genes chromosomes & cancer, 2023-09, Vol.62 (9), p.557-563

2023

Link zum Volltext

Verfügbarkeit prüfen

1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial

Annals of oncology, 2023-10, Vol.34, p.S746-S746

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimal Timing And Technique Of Local Therapy For Brain Metastases From Non-Small Cell Lung Cancer With Driver Mutations

International journal of radiation oncology, biology, physics, 2020-11, Vol.108 (3), p.e718-e718

2020

Link zum Volltext

Verfügbarkeit prüfen

Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells

Hormone and metabolic research, 2008-11, Vol.40 (11), p.752

2008

Link zum Volltext

Verfügbarkeit prüfen

65P Blood cytokine changes in patients with advanced NSCLC receiving immunotherapy

Annals of oncology, 2022-04, Vol.33, p.S61-S62

2022

Link zum Volltext

Verfügbarkeit prüfen

67P Blood cell gene expression and clinical characteristics in advanced non-small cell lung cancer with immune-related adverse events

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S79-S79

2023

Link zum Volltext

Verfügbarkeit prüfen

8P Pre-treatment blood gene expression changes associated with durable clinical benefit in metastatic non-small cell lung cancer with high PD-L1 expression receiving first-line pembrolizumab

Annals of oncology, 2021-12, Vol.32, p.S1377-S1378

2021

Link zum Volltext

Verfügbarkeit prüfen

Hypofractionated Stereotactic Radiotherapy (HFSRT) of the Resection Cavity vs. Whole-Brain Radiotherapy (WBRT) Following Brain Metastasis Resection – Results of the ESTRON Randomized Phase 2 Trial

International journal of radiation oncology, biology, physics, 2023-11, Vol.117 (4), p.e8-e9

2023

Link zum Volltext

Verfügbarkeit prüfen

Stereotactic Radiosurgery for 1-10 Brain Metastases Avoids Whole-Brain Radiotherapy - Results of the CYBER-SPACE Randomized Phase 2 Trial

International journal of radiation oncology, biology, physics, 2023-11, Vol.117 (4), p.e8-e8

2023

Link zum Volltext

Verfügbarkeit prüfen

Stereotactic Radiotherapy vs. Whole Brain Radiation Therapy for Patients with 1-10 Brain Metastases from Small Cell Lung Cancer: Results of the Randomized ENCEPHALON (ARO 2018-9) Trial

International journal of radiation oncology, biology, physics, 2023-11, Vol.117 (4), p.e5-e5

2023

Link zum Volltext

Verfügbarkeit prüfen

1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data

Annals of oncology, 2023-10, Vol.34, p.S1060-S1060

2023

Link zum Volltext

Verfügbarkeit prüfen

EP08.01-031 Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S351-S352

2022

Link zum Volltext

Verfügbarkeit prüfen

40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S37-S38

2023

Link zum Volltext

Verfügbarkeit prüfen

54P Determining the utilization and clinical impact of platinum-etoposide for treatment of small cell lung cancer in the routine setting

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S725-S725

2021

Link zum Volltext

Verfügbarkeit prüfen

EP1.11-20 A Panel of Liquid Biomarkers for Early Response Capturing of NSCLC Therapies in Advanced Stages

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S1014-S1014

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma

Polyglactin 910 suture compared with polyglactin 910 coated with triclosan in dental implant surgery: randomized clinical trial

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing

Retrospective study of paclitaxel in advanced therapy lines in the treatment of SCLC

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial

TP53 mutations impair overall survival of TKI-treated patients with oncogene-driven NSCLC

Durvalumab in frail and elder patients with stage four NSCLC: The DURATION trial

Ultra-early response capturing in the treatment of non-squamous NSCLC using diffusion-weighted MRI: A prospective multicenter study

Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Real‐world data for precision cancer medicine—A European perspective

1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial

Optimal Timing And Technique Of Local Therapy For Brain Metastases From Non-Small Cell Lung Cancer With Driver Mutations

Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells

65P Blood cytokine changes in patients with advanced NSCLC receiving immunotherapy

67P Blood cell gene expression and clinical characteristics in advanced non-small cell lung cancer with immune-related adverse events

8P Pre-treatment blood gene expression changes associated with durable clinical benefit in metastatic non-small cell lung cancer with high PD-L1 expression receiving first-line pembrolizumab

Hypofractionated Stereotactic Radiotherapy (HFSRT) of the Resection Cavity vs. Whole-Brain Radiotherapy (WBRT) Following Brain Metastasis Resection – Results of the ESTRON Randomized Phase 2 Trial

Stereotactic Radiosurgery for 1-10 Brain Metastases Avoids Whole-Brain Radiotherapy - Results of the CYBER-SPACE Randomized Phase 2 Trial

Stereotactic Radiotherapy vs. Whole Brain Radiation Therapy for Patients with 1-10 Brain Metastases from Small Cell Lung Cancer: Results of the Randomized ENCEPHALON (ARO 2018-9) Trial

1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data

EP08.01-031 Blood Gene Expression Changes in Metastatic Lung Cancer under second-line Immunotherapy according to Clinical Response

40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC

54P Determining the utilization and clinical impact of platinum-etoposide for treatment of small cell lung cancer in the routine setting

EP1.11-20 A Panel of Liquid Biomarkers for Early Response Capturing of NSCLC Therapies in Advanced Stages

Suchergebnisse filtern